Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Tables)

Fair Value (Tables)

9 Months Ended

Sep. 30, 2018

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of September 30, 2018
	Level 1		Level 2		Level 3		Total
Money market funds	$	8,585	$	—	$	—	$	8,585
U.S. treasury bills		—		4,248		—		4,248
Government-sponsored enterprise securities		—		14,489		—		14,489
Corporate bonds and commercial paper		—		84,334		—		84,334
Total	$	8,585	$	103,071	$	—	$	111,656


	Assets at Fair Value as of December 31, 2017
	Level 1		Level 2		Level 3		Total
Money market funds	$	2,795	$	—	$	—	$	2,795
U.S. treasury bills		—		6,726		—		6,726
Government-sponsored enterprise securities		—		7,826		—		7,826
Corporate bonds and commercial paper		—		97,822		—		97,822
Total	$	2,795	$	112,374	$	—	$	115,169